Amivantamab (JNJ-61186372)

Overview
Amviantamab (JNJ-61186372) is a bispecific antibody that targets EGFR and cMet, two validated cancer targets. Amviantamab was created under a collaboration between Genmab and Janssen Biotech, Inc. using Genmab’s DuoBody® technology. The two antibodies used to create Amviantamab were both created by Genmab. 

Clinical studies
Amviantamab is being investigated in Phase II clinical studies to treat non-small cell lung cancer (NSCLC).